Nicox S.A. – pharmaceutical daily

August 18, 2017 Off

Nicox responds to the CRL from USFDA for latanoprostene bunod

Paris-listed international ophthalmic company Nicox, on Friday said that its exclusive licensee has said it has submitted a response to the Complete Response Letter (CRL) received from the U.S. Food and Drug Administration (FDA) on August 7, 2017 concerning the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024% for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.

August 15, 2017 Off

Opthalmic company Nicox cashes €26.25 million from 3.5M new ordinary shares

By Dino Mustafić

Nicox S.A. the international ophthalmic company, today announced a reserved capital increase of its ordinary shares to a specific category of investors. The gross proceeds from the financing are €26.25 million, for a total of 3,500,000 new ordinary shares.

May 17, 2017 Off

Nicox welcomes new Board member

By Dino Mustafić

Nicox, the international ophthalmic R&D company, appointed Lauren P. Silvernail to the its Board of Directors, for a period of four years.

February 21, 2017 Off

Nicox presents positive preclinical results for its eye drug

By Dino Mustafić

Nicox, the international ophthalmic R&D company has presented preclinical results from its novel nitric oxide (NO) donating compound, NCX 667 at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy.

January 24, 2017 Off

Nicox to test new eye drug

By Dino Mustafić

Nicox, the international ophthalmic R&D company, has provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide…

November 9, 2016 Off

Nicox: update on Latanoprostene bunod and AC-170

By Dino Mustafić

Nicox S.A., the international ophthalmic R&D company, has provided an update on the regulatory status of its key projects, latanoprostene bunod and AC-170.